Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

14 Mar 2022

Abstract excerpt

BACKGROUND: Treatment of Diffuse Large B Cell Lymphoma (DLBCL) patients with rituximab and the CHOP treatment regimen is associated with frequent intrinsic and acquired resistance. However, treatment with a CD47 monoclonal antibody in combination with rituximab yielded high objective response rates in patients with relapsed/refractory DLBCL in a phase I trial. Here, we report on a new bispecific and fully human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35287686
DOI: 10.1186/s13046-022-02256-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunityPMID 35287686Read ↗

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα AxisSemantic proximity Read ↗

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpointSemantic proximity Read ↗

Recent Advances of Tumor Therapy Based on the CD47-SIRPα AxisSemantic proximity Read ↗

Blockade of CD47 or SIRPα: a new cancer immunotherapySemantic proximity Read ↗

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.Semantic proximity Read ↗

Targeting CD47: the achievements and concerns of current studies on cancer immunotherapySemantic proximity Read ↗

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.Semantic proximity Read ↗

A Novel Anti-CD47 Nanobody Tetramer for Cancer TherapySemantic proximity Read ↗

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destructionSemantic proximity Read ↗

An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunitySemantic proximity Read ↗

Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.Semantic proximity Read ↗

The CD47-SIRP signalling system: its physiological roles and therapeutic applicationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.